Can a digital medicine system improve adherence to antipsychotic treatment?
Epidemiol Psychiatr Sci
; 27(3): 227-229, 2018 06.
Article
en En
| MEDLINE
| ID: mdl-29528032
ABSTRACT
A substantial proportion of people with mental health conditions do not adhere to prescribed pharmacological treatments. Poor adherence is probably one of the most critical elements contributing to relapse in people with schizophrenia and other severe mental disorders. In order to tackle this global issue, in November 2017 the Food and Drug Administration approved a tablet formulation of the atypical antipsychotic aripiprazole embedded with a novel digital adherence-assessment device. In this commentary, we critically appraised the potential beneficial and harmful consequences of this new digital formulation of aripiprazole, and we highlighted expected implications for clinical practice.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Trastornos Psicóticos
/
Antipsicóticos
/
Telemedicina
/
Cumplimiento de la Medicación
/
Aripiprazol
Límite:
Humans
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Epidemiol Psychiatr Sci
Año:
2018
Tipo del documento:
Article
País de afiliación:
Italia